Prinaberel (ERB-041) is a potent and selective ERbeta agonist that demonstrates anticancer and anti-inflammatory activity. It has been studied in models of endometriosis, where its ability to inhibit NF-kappaB signaling, reduce proliferation, and induce apoptosis has been investigated in both in vitro and in vivo experimental settings.
